Spangelo B L, Judd A M, Isakson P C, MacLeod R M
Department of Medicine, University of Virginia Health Sciences Center, Charlottesville 22908.
Endocrinology. 1991 Jun;128(6):2685-92. doi: 10.1210/endo-128-6-2685.
We have reported previously that anterior pituitary cells released interleukin-6 (IL-6) and that this release was stimulated by lipopolysaccharide (LPS), phorbol myristate acetate (PMA), or agents that increased intracellular cAMP concentrations. We now report that IL-1 stimulates IL-6 release from anterior pituitary cells in vitro. IL-1 alpha and IL-1 beta (0.04-25 ng/ml) significantly increased IL-6 release 3- to 4-fold in a concentration-related manner during 6-h incubations; however, there was no change in extracellular or intracellular cAMP concentrations. IL-1 alpha and IL-1 beta (10 ng/ml), vasoactive intestinal peptide (VIP, 500 nM), prostaglandin E2 (PGE2, 1 microM), and LPS (1 ng/ml) stimulated IL-6 release to a similar degree. In the presence of VIP and PGE2, IL-1 alpha and IL-1 beta increased IL-6 release without any apparent further change in extracellular or intracellular cAMP. Conversely, LPS did not increase cAMP concentrations, and IL-1 did not significantly increase IL-6 release in the presence of LPS. The preexposure of anterior pituitary cells to 1 microM PMA caused the apparent down-regulation of protein kinase C activity because 100 nM PMA was no longer effective to stimulate IL-6 release; however, the ability of IL-1 alpha, IL-1 beta, PGE2, or LPS to stimulate IL-6 release was not altered. In addition, IL-1 alpha and IL-1 beta stimulated IL-6 release in the presence of maximally stimulative concentrations of PMA. The synthetic glucocorticoid dexamethasone (10 nM) significantly inhibited IL-6 release induced by IL-1 alpha, IL-1 beta, or LPS. The separation of anterior pituitary cells on unit gravity BSA gradients generated fractions of IL-6-producing cells that were inducible by LPS and IL-1 beta and separate from the PRL-, ACTH-, GH-, or LH-producing cell fractions. These data suggest that IL-1 stimulates IL-6 release from a subpopulation of anterior pituitary cells via a glucocorticoid-sensitive and non-cAMP-mediated pathway that is different from those pathways used by VIP, PGE2, and PMA.
我们之前曾报道,垂体前叶细胞可释放白细胞介素-6(IL-6),且脂多糖(LPS)、佛波酯(PMA)或能提高细胞内cAMP浓度的物质可刺激这种释放。我们现在报道,IL-1在体外可刺激垂体前叶细胞释放IL-6。在6小时的孵育过程中,IL-1α和IL-1β(0.04 - 25 ng/ml)以浓度相关的方式显著增加IL-6释放3至4倍;然而,细胞外或细胞内cAMP浓度没有变化。IL-1α和IL-1β(10 ng/ml)、血管活性肠肽(VIP,500 nM)、前列腺素E2(PGE2,1 μM)和LPS(1 ng/ml)刺激IL-6释放的程度相似。在存在VIP和PGE2的情况下,IL-1α和IL-1β增加IL-6释放,而细胞外或细胞内cAMP没有任何明显的进一步变化。相反,LPS不会增加cAMP浓度,且在存在LPS的情况下,IL-1不会显著增加IL-6释放。垂体前叶细胞预先暴露于1 μM PMA会导致蛋白激酶C活性明显下调,因为100 nM PMA不再能有效刺激IL-6释放;然而,IL-1α、IL-1β、PGE2或LPS刺激IL-6释放的能力没有改变。此外,在存在最大刺激浓度PMA的情况下,IL-1α和IL-1β仍能刺激IL-6释放。合成糖皮质激素地塞米松(10 nM)显著抑制由IL-1α、IL-1β或LPS诱导的IL-6释放。通过单位重力牛血清白蛋白梯度分离垂体前叶细胞,产生了可被LPS和IL-1β诱导的IL-6产生细胞组分,且与产生PRL、ACTH、GH或LH的细胞组分分离。这些数据表明,IL-1通过一种糖皮质激素敏感且非cAMP介导的途径刺激垂体前叶细胞亚群释放IL-6,该途径不同于VIP、PGE2和PMA所使用的途径。